AEON Biopharma (AEON) News Today → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free AEON Stock Alerts $1.73 +0.07 (+4.22%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAEON Biopharma Provides Update on Development Pipelineglobenewswire.com - May 9 at 8:00 AMHC Wainwright Reiterates "Buy" Rating for AEON Biopharma (NASDAQ:AEON)americanbankingnews.com - May 8 at 4:58 AMMaintaining Buy on AEON Biopharma: Potential of ABP-450 Despite Phase 2 Setbackmarkets.businessinsider.com - May 7 at 11:22 AMAEON Biopharma's (AEON) Buy Rating Reiterated at HC Wainwrightmarketbeat.com - May 6 at 8:07 AMNewly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday - Read Here Whymsn.com - May 3 at 8:59 PMUS Equity Markets Close Higher Friday Following Weak Jobs Reportfinance.yahoo.com - May 3 at 8:59 PMAEON Says Preliminary Results From Phase 2 Interim Analysis Of ABP-450 Fails To Meet Primary Goalmarkets.businessinsider.com - May 3 at 9:36 AMAEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraineglobenewswire.com - May 3 at 7:00 AMHC Wainwright Analysts Boost Earnings Estimates for AEON Biopharma, Inc. (NASDAQ:AEON)marketbeat.com - April 19 at 8:31 AMAEON Biopharma: Buoyant Prospects Following FDA Alignment on Migraine Studiesmarkets.businessinsider.com - April 18 at 9:41 AMAEON Biopharma, Inc. Forecasted to Earn Q1 2025 Earnings of ($0.29) Per Share (NASDAQ:AEON)marketbeat.com - April 18 at 6:31 AMAEON Biopharma (NASDAQ:AEON) Earns "Buy" Rating from HC Wainwrightmarketbeat.com - April 17 at 3:30 PMCORRECTION -- AEON Biopharma Announces Redemption of Public Warrantsglobenewswire.com - March 30 at 10:53 PMAEON Biopharma Announces Redemption of Public Warrantsglobenewswire.com - March 29 at 4:15 PMAEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 29 at 3:45 PMLenz stock rallies 22% amid bullish note by Piper Sandlerseekingalpha.com - March 28 at 2:28 PMAEON Biopharma secures $15 million in private placementinvesting.com - March 21 at 6:38 PMAEON Biopharma (NASDAQ:AEON) Shares Gap Down to $14.40marketbeat.com - March 20 at 11:56 AMAEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraineglobenewswire.com - March 19 at 4:30 PMAEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreementsglobenewswire.com - March 19 at 4:29 PMAEON Biopharma (NASDAQ:AEON) Shares Down 7.2% marketbeat.com - March 19 at 12:47 PMAEON Biopharma (NASDAQ:AEON) Reaches New 12-Month High at $15.98marketbeat.com - March 18 at 10:55 AMAEON Biopharma (NASDAQ:AEON) Sees Strong Trading Volumemarketbeat.com - March 15 at 2:18 PMAEON Biopharma, Inc. Class Aedition.cnn.com - February 26 at 12:36 PMDaewoong Pharmaceutical Co., Ltd.: Daewoong Pharmaceutical Announces 2023 Financial Resultsfinanznachrichten.de - February 6 at 12:36 PMAeon Kyushu Co Ltd 2653morningstar.com - February 1 at 11:00 PMAEON.WS AEON Biopharma, Inc. WT EXP 072128seekingalpha.com - January 31 at 10:48 PMAEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conferencefinance.yahoo.com - January 18 at 8:09 PMAeon Fantasy Co Ltd (4343)investing.com - January 10 at 8:27 AMXeris Biopharma Holdings Inc XERSmorningstar.com - December 20 at 12:56 AMAEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migrainefinance.yahoo.com - December 12 at 9:52 AMAEON Biopharma Inc Reports Q3 2023 Financial Results Amid Clinical Advancementsfinance.yahoo.com - November 15 at 10:25 AMAEON Biopharma, Inc. GAAP EPS of -$0.04msn.com - November 14 at 8:31 AMAEON Biopharma Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 13 at 10:05 AM Get AEON Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. AEON Media Mentions By Week AEON Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AEON News Sentiment▼-0.050.58▲Average Medical News Sentiment AEON News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AEON Articles This Week▼51▲AEON Articles Average Week Get AEON Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CKPT News CALC News KZR News EGRX News ANVS News IMMX News RPHM News CELU News ALRN News EQ News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AEON) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressCollapse of the Petrodollar Colonial Metals[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
